Novabay Pharmaceuticals Inc Buchwert je Aktie
Was ist das Buchwert je Aktie von Novabay Pharmaceuticals Inc?
Buchwert je Aktie von Novabay Pharmaceuticals Inc ist 0.49
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf NYSEMKT im Vergleich zu Novabay Pharmaceuticals Inc
Was macht Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Unternehmen mit buchwert je aktie ähnlich Novabay Pharmaceuticals Inc
- Townsquare Media Inc hat Buchwert je Aktie von 0.49
- Kathmandu hat Buchwert je Aktie von 0.49
- NZME hat Buchwert je Aktie von 0.49
- X-Terra Resources hat Buchwert je Aktie von 0.49
- TAV Havalimanlari AS hat Buchwert je Aktie von 0.49
- 17033 hat Buchwert je Aktie von 0.49
- Novabay Pharmaceuticals Inc hat Buchwert je Aktie von 0.49
- Laramide Resources hat Buchwert je Aktie von 0.49
- Mobotix AG hat Buchwert je Aktie von 0.49
- Fab-Form Industries hat Buchwert je Aktie von 0.49
- Fireweed Zinc hat Buchwert je Aktie von 0.49
- Century Ginwa Retail hat Buchwert je Aktie von 0.49
- Eurasia Fonciere Investissements Societe Anonyme hat Buchwert je Aktie von 0.49